RT Journal Article
T1 Evaluating the effectiveness and safety of mepolizumab in elderly patients with severe asthma: insights from the REDES study
A1 Martínez-Moragón, Eva
A1 Pinedo Sierra, Celia María
A1 Puente Maestu, Luis
A1 Muñoz-Esquerre, Mariana
A1 Gómez-Bastero, Ana
A1 Ramos, Jacinto
A1 Díaz-Palacios, Miguel
A1 Hermida, Tamara
A1 Bañas-Conejero, David
A1 Quirce, Santiago
AB Objective: Asthma and severe asthma are problems affecting all age groups, but asthma isfrequently undiagnosed in the elderly, due to the poor perception of airflow limitation, lackof fitness, and presence of multiple comorbidities. Even so, the proportion of patients withsevere asthma aged ≥65 is significant, and data on efficacy of asthma medications in theelderly are sometimes limited. We report here the effectiveness and safety of mepolizumab(an IL-5 inhibitor) in elderly (≥65 years) patients.Methods: The REDES study was an observational, multicenter study of the effectiveness andsafety of mepolizumab 100 mg SC every 4 weeks in 318 severe asthma patients in Spain. Thispost-hoc analysis compares the effectiveness and safety of patients ≥65 years old to patients<65 years after 12 months of mepolizumab treatment.Results: 27% of patients were ≥65 years old, compared with 73% of patients <65 years. Elderlypatients showed a trend toward less frequent comorbid nasal polyps (p = 0.06) and a lowerproportion of atopic sensitization (as detected by prick test or specific IgE) (p = 0.02). Similarimprovements were noted in ACT score (p < 0.0001), comparable exacerbation reductions(p < 0.0001), and lung function parameters (p < 0.04 in elder group and p < 0.0001 in youngerelder group), although an apparent greater reduction of OCS daily dose was observed inelder patients (p = 0.0002). No new safety signals were reported in the elderly population.Conclusions: This study further supports mepolizumab as an effective and well toleratedtherapy in the difficult to treat population of elderly patients with severe asthma.
PB Taylor& Francis
SN 1532-4303
YR 2025
FD 2025
LK https://hdl.handle.net/20.500.14352/130017
UL https://hdl.handle.net/20.500.14352/130017
LA eng
NO Martínez-Moragón E, Pinedo C, Puente-Maestu L, Muñoz-Esquerre M, Gómez-Bastero A, Ramos J, Díaz-Palacios M, Hermida T, Bañas-Conejero D, Quirce S. Evaluating the effectiveness and safety of mepolizumab in elderly patients with severe asthma: insights from the REDES study. J Asthma. 2025 Jul;62(7):1128-1132. doi: 10.1080/02770903.2025.2463956. Epub 2025 Feb 13. PMID: 39918279.
NO This study was funded by GSK (study number 213172).
DS Docta Complutense
RD 20 ene 2026